Factors affecting achievement of glycemic targets among type 2 diabetes patients in South Asia: Analysis of the CARRS trial.
Glycemic targets
Quality improvement
South Asia
Type 2 diabetes mellitus
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
29
07
2020
revised:
12
10
2020
accepted:
10
11
2020
pubmed:
27
11
2020
medline:
16
3
2021
entrez:
26
11
2020
Statut:
ppublish
Résumé
To assess the predictors of achieving and maintaining guideline-recommended glycemic control in people with poorly controlled type 2 diabetes. We analyzed data from the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) Trial (n = 1146), to identify groups that achieved guideline-recommended glycemic control (HbA1c < 7%) and those that remained persistently poorly controlled (HbA1c > 9%) over a median of 28 months of follow-up. We used generalized estimation equations (GEE) analysis for each outcome i.e. achieving guideline-recommended control and persistently poorly controlled and constructed four regression models (demographics, disease-related, self-care, and other risk factors) separately to identify predictors of HbA1c < 7% and HbA1c > 9% at the end of the trial, adjusting for trial group assignment and site. In the final multivariate model, adherence to prescribed medications (RR: 1.46, 95%CI: 1.09, 1.95), adherence to diet plans (RR: 1.79, 95% CI: 1.43, 2.23) and middle-aged: 50-64 years (RR: 1.32; 95% CI: 1.02-1.71) were associated with achieving guideline-recommended control (HbA1c < 7%). Presence of microvascular complications (RR: 0.70; 95%CI: 0.53-0.92) reduced the probability of achieving guideline-recommended glycemic control (HbA1c 7%). Further, longer duration of diabetes (>15 years), RR: 1.41; 95% CI: 1.15, 1.72, hyperlipidemia, RR: 1.19; 95% CI: 1.06, 1.34 and younger age group (35-49 years vs. >64 years: RR: 0.61; 95% CI: 0.47-0.79) were associated with persistently poor glycemic control (HbA1c > 9%). To achieve and maintain guideline-recommended glycemic control, care delivery models must put additional emphasis and effort on patients with longer disease duration, younger people and those having microvascular complications and hyperlipidemia.
Identifiants
pubmed: 33242515
pii: S0168-8227(20)30812-3
doi: 10.1016/j.diabres.2020.108555
pmc: PMC7854496
mid: NIHMS1649369
pii:
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108555Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268200900026C
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW011164
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None of the authors have any potential conflict of interest to declare.
Références
J Assoc Physicians India. 2001 Jul;49:717-22
pubmed: 11573557
Patient Prefer Adherence. 2015 Sep 14;9:1303-14
pubmed: 26396502
Diabetes Care. 2013 Sep;36(9):2628-38
pubmed: 23628621
Diabetes Care. 2019 Mar;42(3):416-426
pubmed: 30104301
Diabetes Res Clin Pract. 2015 Feb;107(2):203-23
pubmed: 25529849
Diabetes Care. 2020 Aug;43(8):1673-1678
pubmed: 32669405
Diabetes Res Clin Pract. 2012 Nov;98(2):285-94
pubmed: 23084280
Lancet. 2017 Dec 2;390(10111):2437-2460
pubmed: 29150201
Diabetes Care. 2000 Mar;23(3):273-7
pubmed: 10868850
Diabetes Res Clin Pract. 2015 Nov;110(2):172-82
pubmed: 26432412
Int J Nurs Stud. 2008 Oct;45(10):1525-33
pubmed: 18439609
BMC Public Health. 2005 Apr 17;5:36
pubmed: 15833140
J Diabetes Complications. 2012 May-Jun;26(3):181-6
pubmed: 22520403
Br J Gen Pract. 2003 May;53(490):389-91
pubmed: 12830567
Diabetes Care. 2013 Jun;36(6):1541-6
pubmed: 23275370
Drug Healthc Patient Saf. 2014 Oct 24;6:155-65
pubmed: 25368533
JAMA Intern Med. 2019 Aug 12;:
pubmed: 31403658
BMC Res Notes. 2019 Apr 4;12(1):207
pubmed: 30947749
Lancet. 2011 Jul 9;378(9786):156-67
pubmed: 21705063
BMC Res Notes. 2017 Nov 15;10(1):597
pubmed: 29141693
Chin Med J (Engl). 2011 Aug;124(16):2461-8
pubmed: 21933588
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
Ann Intern Med. 2016 Sep 20;165(6):399-408
pubmed: 27398874
BMC Res Notes. 2016 Feb 09;9:78
pubmed: 26861243
Metabolism. 2020 Jun;107:154218
pubmed: 32222374
Lancet Glob Health. 2018 Dec;6(12):e1352-e1362
pubmed: 30219315
Lancet. 2012 Jun 16;379(9833):2252-61
pubmed: 22683130
Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596
pubmed: 28601585